Decreased cathepsin V expression due to Fli1 deficiency contributes to the development of dermal fibrosis and proliferative vasculopathy in systemic sclerosis.
about
Fli1 represses transcription of the human α2(I) collagen gene by recruitment of the HDAC1/p300 complex.Fibrosis, vascular activation, and immune abnormalities resembling systemic sclerosis in bleomycin-treated Fli-1-haploinsufficient miceAnimal models of scleroderma: current state and recent development.Vasculopathy in scleroderma.Recent advances in animal models of systemic sclerosis.Endothelin receptor blockade ameliorates vascular fragility in endothelial cell-specific Fli-1-knockout mice by increasing Fli-1 DNA binding ability.Fli1 deficiency contributes to the suppression of endothelial CXCL5 expression in systemic sclerosis.A possible contribution of endothelial CCN1 downregulation due to Fli1 deficiency to the development of digital ulcers in systemic sclerosis.Increased expression of chemerin in endothelial cells due to Fli1 deficiency may contribute to the development of digital ulcers in systemic sclerosis.Fli1 deficiency contributes to the downregulation of endothelial protein C receptor in systemic sclerosis: a possible role in prothrombotic conditions.Epithelial Fli1 deficiency drives systemic autoimmunity and fibrosis: Possible roles in scleroderma.A potential contribution of antimicrobial peptide LL-37 to tissue fibrosis and vasculopathy in systemic sclerosis.The Multifaceted Role of the Lysosomal Protease Cathepsins in Kidney Disease.A possible implication of reduced levels of LIF, LIFR, and gp130 in vasculopathy related to systemic sclerosis.Fli1 deficiency and beyond: a unique pathway linking peripheral vasculopathy and dermal fibrosis in systemic sclerosis.Single Cell RNA Sequencing Identifies HSPG2 and APLNR as Markers of Endothelial Cell Injury in Systemic Sclerosis Skin
P2860
Q34994922-2C3FE219-3DB2-4847-B517-8A5EC0FF8B0FQ35127552-D8975785-7302-45F1-BD35-6C33DF765F35Q38154834-89C26F8B-C9AB-428B-8663-5F6490E6C4ECQ38543688-FD461A2B-1979-42C3-8192-D93A19D02BCBQ38701983-A323E69D-2838-4498-91A4-8DA10F2E62A0Q38868948-F87ECC3B-059C-4FA7-AC13-177DB33DE4E0Q40154356-7FE018FA-B456-4DD6-AB47-60B112E21469Q40236906-D228D9E5-1E57-475D-BFE8-CC706B281317Q40245857-BB116529-F4FB-4CF5-B939-A5E6CD96E382Q40316188-DF17BF59-B53B-4D41-B2FC-C243F550EB7FQ40321155-D806FF43-8B9D-4FE7-8C11-831E401A5F56Q40368781-B7253F3E-6EF1-4644-9517-D09BF5A95865Q47171560-3D01948E-05B2-4606-9E63-71311FF110E1Q48177844-024040EB-7FD2-42E8-8985-5A8F41CF7462Q53662594-127210CF-D8C2-4FA4-B7C9-B5070952C1CBQ57486499-24F095DD-726D-4B9C-98A7-A88CFB188FD2
P2860
Decreased cathepsin V expression due to Fli1 deficiency contributes to the development of dermal fibrosis and proliferative vasculopathy in systemic sclerosis.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Decreased cathepsin V expressi ...... lopathy in systemic sclerosis.
@en
Decreased cathepsin V expressi ...... lopathy in systemic sclerosis.
@nl
type
label
Decreased cathepsin V expressi ...... lopathy in systemic sclerosis.
@en
Decreased cathepsin V expressi ...... lopathy in systemic sclerosis.
@nl
prefLabel
Decreased cathepsin V expressi ...... lopathy in systemic sclerosis.
@en
Decreased cathepsin V expressi ...... lopathy in systemic sclerosis.
@nl
P2093
P2860
P356
P1433
P1476
Decreased cathepsin V expressi ...... lopathy in systemic sclerosis.
@en
P2093
Hayakazu Sumida
Kaname Akamata
Koichi Yanaba
Makoto Sugaya
Naohiko Aozasa
Shinichi Sato
Shinji Noda
Takafumi Kadono
Takashi Taniguchi
Takehiro Takahashi
P2860
P304
P356
10.1093/RHEUMATOLOGY/KES379
P577
2013-01-03T00:00:00Z